Regulation of transglutaminase activity in articular chondrocytes through thrombin receptor-mediated factor XIII synthesis

Summary

Transglutaminases are a family of enzymes that catalyze the formation of ɛ-(γ-glutamyl)lysine isopeptide bonds in proteins, an activity that has been implicated in the pathogenesis of cartilage matrix mineralization in degenerative arthritis. Type II transglutaminase and thrombin-activatable factor XIII have been identified in articular cartilage. Thrombin, a coagulation protease, is found in pathological synovial fluids, and is known to stimulate transglutaminase activity in non-articular tissues. We investigated the effects of thrombin on transglutaminase activity in porcine articular chondrocytes. Direct addition of thrombin to chondrocyte lysates resulted in increased transglutaminase activity due to proteolytic conversion of factor XIII to XIIIa. Thrombin-treated chondrocyte cultures (0.001 to 2.0U/ml) also showed increased transglutaminase activity. Thrombin treatment of chondrocyte cultures increased transglutaminase activity as early as 15 minutes after addition, an effect that we attributed to factor XIII activation. Additional stimulatory effects of thrombin were observed in cultured chondrocytes at 4 and 24 hours. A thrombin receptor agonist peptide (TRAP) which activates the PAR1 thrombin receptor mimicked these later effects. Thrombin treatment of chondrocyte cultures increased factor XIII mRNA and protein levels, without affecting levels of type II transglutaminase. Thus, thrombin stimulates transglutaminase activity in articular cartilage by directly cleaving factor XIII and by receptor-mediated upregulation of factor XIII synthesis. Such increases in potential transglutaminase activity may facilitate pathological matrix calcification in degenerative arthritis.

Keywords

Degenerative arthritis - calcium pyrophosphate crystals - mineralization - proteases - articular cartilage

• References

• 1 Johnson K, Hashimoto S, Lotz M. et al. Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIIa. Am J Pathol 2001; 159: 149-63.
• 2 Rosenthal A, Henry L. Enhanced CPPD crystal deposition by aging chondrocytes is dependent on transglutaminase activity. Arthritis Rheum. 1998: S237.
• 3 Johnson K, van Etten D, Nanda H. et al. Distinct transglutaminase 2-independent and transglutaminase 2-dependent pathways mediate articular chondrocyte hypertrophy. J Biol Chem 2003; 278: 18824-32.
• 4 Lorand L, Graham R. Transglutaminases: crosslinking enzymes with pleiotrophic functions. Nature 2003; 04: 140-57.
• 5 Rosenthal AK, Derfus BA, Henry LA. Transglutaminase activity in aging articular chondrocytes and articular cartilage vesicles. Arthritis Rheum 1997; 40: 966-70.
• 6 Rosenthal A, Masuda I, Gohr C. et al. The transglutaminase, Factor XIIIA , is present in articular chondrocytes. Osteoarthritis Cartilage 2001; 09: 578-81.
• 7 Rosenthal A, Cheung H, Ryan L. Transforming growth factor beta 1 stimulates inorganic pyrophosphate elaboration by porcine cartilage. Arthritis Rheum 1991; 34: 904-11.
• 8 Rosenthal A, Gohr C, Henry L. et al. Participation of transglutaminase in the activation of latent transforming growth factor β1 in aging articular cartilage. Arthritis Rheum 2000; 43: 1729-33.
• 9 Muszbek L, Yee V, Hevessy Z. Blood coagulation factor XIII: Structure and function. Thromb Res 1999; 94: 271-305.
• 10 Siebenlist K, Meh D, Mosesson M. Protransglutaminase (Factor XIII) mediated crosslinking of fibrinogen and fibrin. Thromb Haemost 2001; 86: 1221-8.
• 11 Nurminskaya M, Magee C, Nurminsky D. et al. Plasma transglutaminase in hypertrophic chondrocytes:expression and cell-specific intracellular activation produce cell death and externalization. J Cell Biol 1998; 142 (04) 1135-44.
• 12 Chang P, Aronson D, Borenstein D. et al. Coagulant proteins and thrombin generation in synovial fluid: A model for extravascular coagulation. Am J Hematol 1995; 50: 79-83.
• 13 Nakano S, Ikata T, Kinoshita I. et al. Characteristics of the protease activity in synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Clin Exp Rheumatol 1999; 17: 161-70.
• 14 Furmaniak-Kazmierczak E, Cooke T, Manuel R. et al. Studies of thrombin-induced proteoglycan release in the degradation of human and bovine cartilage. J Clin Invest 1994; 94: 472-80.
• 15 Grand R, Turnell A, Grabham P. Cellular consequences of thrombin-receptor activation. Biochem J 1996; 313: 353-68.
• 16 Coughlin S. How the protease thrombin talks to cells. Proc Natl Acad Sci, USA 1999; 95: 11023-7.
• 17 Auld G, Ritchie H, Robbie L. et al. Thrombin upregulates tissue transglutaminase in endothelial cells. Arterioscler Thromb Vasc Biol 2001; 21: 1689-94.
• 18 Muszbek L, Polgar J, Boda Z. Platelet Factor XIII becomes active without the release of activation peptide during platelet activation. Thromb Haemost 1993; 69: 282-5.
• 19 Mitchell P, Struve J, McCarthy G. et al. Basic calcium phosphate crystals stimulate cell proliferation and collagenase message accumulation in cultured adult articular chondrocytes. Arthritis Rheum 1992; 35: 343-50.
• 20 Lowry O, Rosebrough N, Farr A. et al. Protein measurement with Folin-phenol reagent. J Biol Chem 1951; 193: 265-75.
• 21 Lorand L, Gotoh T. Fibrinoligase. the fibrin stabilizing factor. Methods Enzymol 1970; 19: 663-74.
• 22 Curtis C, Stenberg P, Chou C-H. et al. Titration and subunit localization of active center cysteine in fibrinoligase. Biochem Biophys Res Comm 1973; 52: 51-6.
• 23 Chung S, Lewis M, Folk J. Relationships of the catalytic properties of human plasma and platelet transglutaminases (activated blood coagulation factor XIII) to their subunit structures. J Biol Chem 1974; 249: 940-50.
• 24 Ichinose A, Hendrickson L, Fujikawa K. et al. Amino acid sequence of the A subunit of human factor XIII. Biochemistry 1986; 25: 6900-6.
• 25 Gentile V, Saydak M, Chiocca E. et al. Isolation and characterization of cDNA clones to mouse macrophage and human endothelial cell tissue transglutaminase. J Biol Chem 1991; 266: 478-83.
• 26 Collier S, Ghosh P. Evaluation of the effect of anti-arthritic drugs on the secretion of proteoglycans by lapine chondrocytes using a novel assay procedure. Ann Rheum Dis 1989; 48: 372-81.
• 27 Le M, Gohr C, Rosenthal A. Transglutaminase participates in the incorporation of latent TGFβ into the extracellular matrix of aging articular chondrocytes. Conn Tiss Res 2001; 42: 245-53.
• 28 Curtis C, Brown K, Credo R. et al. Calciumdependent unmasking of active center cysteine during activation of fibrin stabilizing factor. Biochemistry 1974; 13: 3774-80.
• 29 Yee V, Pedersen L, Le Trong I. et al. Three dimensional structure of a transglutaminase human blood coagulation factor XIII. Proc Natl Acad Sci, USA 1994; 91: 7296-300.
• 30 Schwartz M, Pizzo S, Hill R. et al. The subunit structures of human plasma and platelet factor XIII (fibrin-stabilizing factor). J Biol Chem 1971; 248: 5851-4.
• 31 Weinberg J, Pippen A, Greenberg C. Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1991; 34: 996-1005.
• 32 Chang P, Aronson D, Borenstein D. et al. Coagulant proteins and thrombin generation in synovial fluid: a model for extravascular coagulation. J Hematol 1995; 50: 79-83.
• 33 Doherty M, Dieppe P. Crystal deposition disease in the elderly. Clinics Rheum Dis 1986; 12: 97-116.
• 34 Lajemi M, Demignot S, Adolphe M. Detection and characterization , using fluoresceincadaverine , of amine acceptor protein substrates accessible to active transglutaminase expressed by rabbit articular chondrocytes. Histochemical J 1998; 30: 499-508.
• 35 O’Brien P, Molino M, Kahn M. et al. Protease activated receptors: theme and variations. Oncogene 2001; 20: 1570-81.
• 36 Nurminskaya M, Linsenmayer T. Analysis of up-regulated genes during chondrocyte hypertrophy. Ann NY Acad Sci 1996; 785: 309-10.
• 37 Kaartinen M, El-Maadawy S, Rasanen N. et al. Tissue transglutaminase and its substrates in bone. J Bone Miner Res 2002; 17: 2161-75.